Dr Marie Ann RoskrowChairperson
Dr Roskrow gained a BSc(Hons), MBBS (Hons) degree and a PhD in Immunology from the University of London. She has more than 25 years of experience as a physician / medical researcher, investment banker, CEO and chairperson in both private and listed companies such as the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). During her 8 years at Lazard, Marie executed a wide-range of complex strategic transactions including: mergers and acquisitions, joint ventures and asset divestitures. Additionally she was involved in the execution of > 50 financing deals including: IPOs, capital raisings and structured debt. Marie holds 0 shares in Biotec Pharmacon
Mr. Wedershoven has a MBA from Ludvig Maximillian University, Munchen, Germany and has a wide background within entrepreneurship, finance and strategy. Mr. Wedershoven has more than 30 years of industrial experience and was amongst others responsible for development of Seidenader Machinenbau, a global supplier of production equipment to the pharmaceutical industry. He sold the company in 2010 with close to 500 employees to a large equipment supplier in Germany. Mr. Wedershoven holds several board and management positions in smaller German companies. Volker holds 80.000 shares in Biotec Pharmacon
Ingrid SkjævelandDirector - employee representative
Ms. Skjæveland holds a Civil Engineer in Biotechnology and a PhD in Immunology from the University of Tromsø. Skjæveland worked as post.doc and a researcher at the University of Tromsø before she joined Biotec BetaGlucan in 2013 as a Scientific Product manager for Woulgan. She was elected as employee representative to the Board in May 2017. Number of shares in Biotec Pharmacon held by Ms. Skjæveland: 16,087.
Marit Sjo LorentzenDirector
Mrs. Lorentzen has a Civil engineering degree in Biotechnology and a Dr. Scient in Molecular Biology degree from the University of Tromsø. Marit worked at the University of Tromsø until 2011. She has extensive work experience within laboratory operations, management and research. This also includes experience within teaching, field of studies in biochemistry, molecular biology, microbiology, fermentation and purification. She holds a position as Production Manager in ArcticZymes. Number of shares in Biotec Pharmacon held by Mrs. Lorentzen: 20,331